Han Wenbo, Zhao Yong, Wang Yahong, Dai Yanyan, Hao Jinhong, Li Tianli, Wang Xian
Dongzhimen Hospital, Affiliated Hospital of Beijing University of Chinese Medcine.
Institute of cardiovascular disease, Beijing University of Chinese Medicine, Beijing, China.
Medicine (Baltimore). 2020 Apr;99(14):e19672. doi: 10.1097/MD.0000000000019672.
Coronary heart disease (CHD) has become the primary cause of heart failure (HF). Wenyang Huoxue method can significantly improve cardiac function in patients with CHD complicated with HF, but it has not been systematically evaluated for efficacy and safety.
We will search China National Knowledge Infrastructure Database, Wanfang database, China Biomedical Literature Database, China Science Journal Database PubMed, Excerpt Medica Database, and Cochrane library. Clinical trial registrations, potential grey literature, related conference abstracts, and reference lists of identified studies will also be retrieved. The electronic database will be searched for literatures published from January 2000 to September 2019. Based on the heterogeneity test, data integration is performed using a fixed effect model or a random effects model. Changes in total effective rate in cardiac function will be assessed as primary outcome. 6-minute walk test, left ventricular ejection fraction, and plasma brain natriuretic peptide will be assessed as secondary outcomes. RevMan 5.3.5 will be used for meta-analysis.
This study will provide a high-quality comprehensive evaluation of the efficacy and safety of Wenyang Huoxue method for treating patients with CHD complicated with HF.
This systematic review will determine whether Wenyang Huoxue method provides evidence for effective intervention in patients with CHD complicated with HF.
This systematic review and meta-analysis of randomized controlled trials does not require ethical recognition, and the results of this paper will be published in an open access, internationally influential academic journal.
CRD42016025957.
冠心病(CHD)已成为心力衰竭(HF)的主要病因。温阳活血法可显著改善冠心病合并心力衰竭患者的心脏功能,但尚未对其疗效和安全性进行系统评价。
我们将检索中国知网数据库、万方数据库、中国生物医学文献数据库、中国科学期刊数据库、PubMed、医学文摘数据库和Cochrane图书馆。还将检索临床试验注册信息、潜在的灰色文献、相关会议摘要以及已识别研究的参考文献列表。检索电子数据库中2000年1月至2019年9月发表的文献。基于异质性检验,使用固定效应模型或随机效应模型进行数据整合。将心功能总有效率的变化作为主要结局进行评估。将6分钟步行试验、左心室射血分数和血浆脑钠肽作为次要结局进行评估。使用RevMan 5.3.5进行荟萃分析。
本研究将对温阳活血法治疗冠心病合并心力衰竭患者的疗效和安全性进行高质量的综合评价。
本系统评价将确定温阳活血法是否为冠心病合并心力衰竭患者的有效干预提供证据。
本随机对照试验的系统评价和荟萃分析无需伦理认可,本文结果将发表在开放获取、具有国际影响力的学术期刊上。
CRD42016025957。